Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343584 | 1.00 | ALOX5 (0.35) | ALOX5NR1H2MEN1HTTKMT2A | |
| SCHEMBL16292529 | 0.94 | ALOX5 (0.39) | ALOX5MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1583907 | 0.89 | NR1H2 (0.35) | NR1H2 | |
| SCHEMBL1498383 | 0.87 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL482201 | 0.87 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL16874912 | 0.87 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL927784 | 0.85 | GABRA5 (0.39) | — | |
| SCHEMBL1192555 | 0.85 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL17440295 | 0.85 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL16337952 | 0.84 | L3MBTL3 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889676-B2 | 3-ureidoisoquinolin-8-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-06 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| EP-2280696-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | ALOX5 690/4885NR1H2 1414/4885MEN1 2654/4885 |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | ALOX5 3974/4885NR1H2 3824/4885MEN1 195/4885 |
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CNR2, CYP2C9, CYP2C8 | ALOX5 460/4885NR1H2 1848/4885MEN1 3071/4885 |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | CBR3, CBR1, REL | ALOX5 1363/4885NR1H2 950/4885MEN1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.